SECTIONS
SUBSCRIBE
Managed Care

Search form

  • News
  • Politics & policy
  • Drug management
  • Payers
  • Providers
  • Current Issue
  • More
    • Past issues
    • Value-Based Care
    • Profiles
    • Conversations
    • Tomorrow's Medicine
    • Original research
    • Pharm D Corner
    • Viewpoints
    • Legislation & regulation
    • Contact Us

Most Popular

“Step Therapy” Approach To Lowering Health Care Costs Raises Concerns

To keep rising health care costs in check, many health insurers have adopted a strategy known as “step therapy,” a policy requiring patients to try cheaper drugs first—and find them to be ineffective—before approving pricier medication. However, some health care experts contend the approach,…
Read more

Praluent Cuts Cardiac Events, Deaths in High-Risk Patients

Alirocumab injection (Praluent, Regeneron Pharmaceuticals/Sanofi) reduced the risk of major cardiac events by 15% among patients who had suffered heart attacks and other coronary events in the ODYSSEY OUTCOMES trial. The two companies have announced that they are willing to offer price breaks on the…
Read more

E-Cigarettes: Less Harmful Than the Conventional Version?

While e-cigarettes are not without health risks, they are likely to be far less harmful than conventional cigarettes, according to a congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine. The committee that conducted the study concluded that e-cigarettes…
Read more

GSK Wins New Reprieve as Hikma’s Generic Advair Is Delayed Again

GlaxoSmithKline (GSK) has won a further reprieve for its blockbuster lung drug Advair (fluticasone propionate and salmeterol inhalation powder) after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug, Reuters reports. The Jordan-based…
Read more

Repeated Influenza Vaccination Helps Prevent Severe Flu in Older Adults

Repeated vaccination for influenza in older adults reduced the severity of the virus and reduced hospital admissions, according to new research published in the Canadian Medical Association Journal. A team of Spanish researchers looked at the effect of repeated influenza vaccinations in the current…
Read more

Boxed Warning Added to Ocaliva Due to Improper Dosing

The FDA is adding a boxed warning to obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc.) in an effort to prevent incorrect dosing of the liver-disease medication in patients with moderate-to-severe primary biliary cholangitis (PBC). Obeticholic acid has been incorrectly dosed daily instead of…
Read more

Keytruda Improves Recurrence-Free Survival After Melanoma Surgery

Pembrolizumab (Keytruda, Merck) significantly improved recurrence-free survival compared with placebo in a phase 3 trial investigating the anti-PD-1 medication as monotherapy for surgically resected high-risk melanoma. Based on an interim analysis and following review by an Independent Data Monitoring…
Read more

Alzheimer’s Drug Targeting Soluble Amyloid Falls Short in Trial

Solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline, according to a report published in The New England Journal of Medicine. Researchers have proposed that Alzheimer’s disease…
Read more

FDA Approves Symdeko to Treat Underlying Cause of Cystic Fibrosis in Certain Patients

The FDA has approved tezacaftor/ivacaftor and ivacaftor (Symdeko, Vertex Pharmaceuticals, Inc.) to treat the underlying cause of cystic fibrosis (CF) in patients 12 years of age and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene…
Read more

FDA Approves Opdivo Label With Expanded Dosing Options

The FDA has approved a supplemental biologics license application updating the dosing schedule of nivolumab (Opdivo, Bristol-Myers Squibb) to include 480 mg infused every four weeks (Q4W) for a majority of approved indications. This approval will give health care professionals the flexibility to customize…
Read more

Apadaz Approved for the Short-Term Management of Acute Pain

The FDA has approved a combination of acetaminophen and the prodrug benzhydrocodone (Apadaz, KemPharm, Inc.) that the manufacturer believes is “a differentiated product for the short-term management of acute pain.”  The FDA approved the immediate-release product for the short-term (no more than…
Read more

Aetna to Offer Point-of-Sale Pharmacy Rebates to Three Million Customers

Aetna, Inc., has announced that it will automatically pass on drug-maker rebates to about three million commercial members at the point of sale beginning in 2019, according to a BioPharma Dive report. The move comes less than a month after UnitedHealth Group, Inc., announced a similar initiative, which…
Read more

This Flu Season’s Toll Is Challenging Records

The flu or pneumonia claimed the lives of one out of every 10 Americans who died during the week ending February 3, according to the Centers for Disease Control and Prevention (CDC). Throughout most of the nation, the flu appears to remain on the rise, Acting CDC Director Anne Schuchat, MD, said at…
Read more

Florida Shooting Reopens CDC Gun Research Debate

A mass shooting at a Florida high school that left 17 people dead has reopened a debate in Congress about loosening long-standing restrictions on Centers for Disease Control and Prevention (CDC) research into gun violence, according to an article in The Hill. Democrats have frequently railed against…
Read more

FDA Approves 0.3-mg Prefilled Syringe for Lucentis Administration

The FDA has approved the ranibizumab injection (Lucentis, Genentech) 0.3-mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy. In April 2017, Lucentis 0.3 mg became, and remains, the first and only FDA-approved medicine to treat all forms…
Read more

Pages

  • « first
  • ‹ previous
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • next ›
  • last »
Facebook Twitter LinkedIn RSS Feed
  • Contact Us
  • Our History
  • Terms & Conditions of Use Agreement
  • Address and Subscription Changes
  • 2018 Editorial Calendar
  • 2018 Space and Material Due Dates
  • BPA Statement
  • Submitting Original Research
  • Submitting Viewpoints
  • Site Map
  • Contact Webmaster
  • P&T Community
© 2018 MediMedia, an ICON plc company. All rights reserved.